Biothera and Biotec Pharmacon ASA announce they have reached a settlement of the litigation between them now pending in federal court in Minneapolis, Minnesota.Although the terms of the settlement are confidential, both companies expressed satisfaction with the outcome.
Daniel Conners, Chairman of Biothera, stated: “The settlement maintains the protection of our intellectual property”.
Lars Viksmoen, CEO of Biotec, says: “The business resolution will allow Biotec Pharmacon to proceed with its drug development programs”.
